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Abstract
Background: Awareness with explicit recall of intra-operative events is a rare and distressing
complication that may lead to severe psychological symptoms. Candidate depth of anesthesia
monitors have been developed, partly with the aim of preventing this complication. Despite
conflicting results from clinical trials and the lack of incisive validation, such monitors have enjoyed
widespread clinical adoption, in particular the bispectral index. The American Society of
Anesthesiologists has called for adequately powered and rigorously designed clinical trials to
determine whether the use of such monitors decreases the incidence of awareness in various
settings. The aim of this study is to determine with increased precision whether incorporating the
bispectral index into a structured general anesthesia protocol decreases the incidence of awareness
with explicit recall among a subset of surgical patients at increased risk for awareness and scheduled
to receive an inhalation gas-based general anesthetic.
Methods/Design: BAG-RECALL is a multi-center, randomized, controlled clinical trial, in which
6,000 patients are being assigned to bispectral index-guided anesthesia (target range, 40 to 60) or
end-tidal anesthetic gas-guided anesthesia (target range, 0.7 to 1.3 age-adjusted minimum alveolar
concentration). Postoperatively, patients are being assessed for explicit recall at two intervals (0 to
72 hours, and 30 days after extubation). The primary outcome of the trial is awareness with explicit
recall. Secondary outcomes include postoperative mortality, psychological symptoms, intensive
care and hospital length of stay, average anesthetic gas administration, postoperative pain and
nausea and vomiting, duration of stay in the recovery area, intra-operative dreaming, and
postoperative delirium.
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Discussion: This trial has been designed to complement two other clinical trials: B-Unaware and
MACS (ClinicalTrials.gov numbers, NCT00281489 and NCT00689091). With the large patient
numbers and complementary rigorous designs, it is envisaged that pre-specified meta-analyses will
address some of the outstanding controversies and questions relating to processed
electroencephalography monitoring.
Trial registration: ClinicalTrials.gov Identifier: NCT00682825
Background
Many patients facing surgery dread the prospect of being
awake, in pain and unable to move owing to inadequate
general anesthesia. Awareness during anesthesia with sub-
sequent explicit recall (AWR) is distressing and may con-
tribute to posttraumatic stress disorder [1-4]. Several
monitors, mostly based on processed electroencephalo-
graph (EEG) information or auditory evoked potentials,
have been developed in an attempt to measure depth of
anesthesia or depth of hypnosis[5]. It is hoped that the
use of such monitors during general anesthesia will
decrease the likelihood of AWR. Of these monitors, the
bispectral index (BIS monitor) has been most widely
adopted in clinical practice. The BIS monitor incorporates
a proprietary algorithm based on signals from a processed
scalp EEG. The monitor shows a dimensionless number
between 0 and 100, with lower numbers reflecting deeper
anesthesia[6,7].
The American Society of Anesthesiologists (ASA) has
issued a practice advisory on AWR[8]. The ASA advisory
does not currently advocate the routine use of brain mon-
itors such as the BIS monitor to prevent AWR as the evi-
dence remains equivocal[8]. According to a Joint
Commission for Accreditation of Healthcare Organiza-
tion (JCAHO) Sentinel Event Alert, between 20,000 and
40,000 cases of anesthesia awareness may occur each year
in the USA alone[9]. The JCAHO Alert states that the use
of BIS monitoring to help guide anesthetic administration
may be associated with a reduction in the incidence of
AWR in adults during general anesthesia and sedation[9].
A large multi-center observational study in the USA
showed that, despite modern anesthesia techniques, the
overall incidence of AWR in the general surgical popula-
tion remains about 0.1-0.2%[4]. In this study, the inci-
dence of AWR was not lower when a BIS monitor was
used, but there was no protocol for anesthesia based on
the BIS monitor and anesthesia care was not standardized
among centers or practitioners. Some patients are at
higher risk for AWR according to the type of surgery, co-
morbidities, anesthetic techniques (including total intra-
venous anesthesia (TIVA)), chronic medications, sub-
stance misuse, and unidentified genetic factors[8,10-13].
For some of these patients the risk of AWR has been esti-
mated to be as high as 1%[10].
The 2,500 patient multi-center B-Aware Study was
designed to determine whether the BIS monitor might
substantially decrease the incidence of AWR among
patients at higher risk for AWR[10]. The study was pow-
ered to detect a large 0.9% absolute reduction in AWR in
this population because the introduction of BIS monitor-
ing into routine clinical practice would require proof of
clinical efficacy[10,14]. The B-Aware Study found that
incorporation of a BIS-guided protocol decreased the inci-
dence of 'definite' AWR among patients who were at
higher risk by 0.74% (95% CI, 0.08% to 1.5%)[10].
Unlike the multi-center study in the USA referred to above
[4], in the B-Aware Study anesthesiologists followed a
structured protocol when the BIS was used, striving to
titrate anesthesia such that the BIS number was between
40 and 60 for most of the anesthetic period[10]. An alter-
native hypothesis explaining the results of the B-Aware
Study is that the directive to record BIS values at pre-spec-
ified intervals might have heightened the overall level of
vigilance about awareness in the intervention group. Care
was not protocol-driven in the control group, and usual
practice was followed. Another potential confounder in
the B-Aware Study was the pooling of patients who
received TIVA with those who received volatile anesthesia,
since the incidence of AWR and the efficacy of BIS moni-
tors may differ between the two techniques[11,12].
An attempt was made to address some of the potential
confounders in the B-Aware Study in the prospective ran-
domized B-Unaware trial, which enrolled 2,000 patients
at higher risk for AWR, all of whom received inhalation
anesthesia[15,16]. Protocols to increase vigilance during
anesthetic delivery were based on either BIS monitoring
or on end-tidal anesthetic concentration. In the BIS mon-
itored group, volatile anesthetics were titrated to target the
manufacturer's recommended BIS range for surgical
anesthesia. In the control group, the end-tidal anesthetic
agent target was above 0.7 minimum alveolar concentra-
tion (MAC), a concentration that may suppress the forma-
tion of emotionally charged memories[16]. Audible
alarms alerted practitioners when targets were not
achieved. There was no difference in the incidence of 'def-
inite' AWR between the groups, with two cases occurring
in each (difference = 0%; 95% CI, -0.56 to 0.57%)[15].
The results of the B-Unaware trial suggest that for patients
at higher risk for awareness undergoing inhalationBMC Anesthesiology 2009, 9:8 http://www.biomedcentral.com/1471-2253/9/8
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anesthesia with a protocol designed to increase vigilance,
the BIS monitor is very unlikely to decrease the incidence
of 'definite' AWR by 0.9%. But the precision or confidence
interval does not exclude the possibility that BIS may still
be associated with a clinically important reduction in
AWR in this setting of up to 0.57%.
There were additional findings arising from the B-Una-
ware Trial, including the following: 1) The BIS protocol
was not associated with decreased administration of
anesthesia; 2) Cumulative duration of BIS <45 was inde-
pendently associated with increased mortality, independ-
ent of anesthetic dose and protocol arm; 3) The BIS
protocol was not associated with decreased long term psy-
chological symptoms; 4) The BIS protocol was not associ-
ated with more rapid postoperative recovery or decreased
side effects of anesthesia; 5) Dreaming was not associated
with AWR, with mean anesthetic dose, with mean BIS val-
ues, or with the use of the BIS monitor; 6) The BIS proto-
col was not associated with decreased intensive care stay,
decreased hospital stay or decreased mortality. These find-
ings should be regarded as hypothesis generating and
requiring verification or refutation in subsequent trials.
It is important for patients, for regulatory bodies and for
anesthesia practitioners that brain monitors such as the
BIS undergo rigorous evaluation to determine whether
they really do decrease AWR and whether they are cost
effective before they are adopted into routine practice. The
primary purpose of the BAG RECALL trial will therefore be
to answer this question with greater precision in patients
at high risk for AWR undergoing general anesthesia with a
potent inhalation agent. Our companion study, the Mich-
igan Awareness Control Study (MACS, NCT00689091), is
designed to answer this question rigorously in the general
surgical population, regardless of risk for AWR. The sec-
ondary outcomes of BAG-RECALL will address with
increased accuracy the additional findings of the B-Una-
ware Trial, and other important questions. We also plan
meta-analyses including the B-Unaware, MACS and BAG-
RECALL trials.
Methods/Design
Patients
This is a multi-center study that has been approved by the
Human Studies Committees at Washington University in
St Louis, University of Chicago, and University of Mani-
toba. The Consolidated Standards of Reporting Trials
guidelines will be followed in the conduct of the study
and in the reporting of results[17,18]. We are evaluating
patients, who are older than 18 years and who are under-
going surgery, for eligibility prior to their surgery on the
basis of preoperative assessment records. Patients are
required to be at high risk for AWR, and to have general
anesthesia with isoflurane, sevoflurane, or desflurane,
without supplemental nitrous oxide. The criteria for iden-
tifying patients at high risk for AWR have been based on
previous studies, reviews, and guidelines. Patients at high
risk are defined as those with at least one risk factor. The
pre-specified risk factors are preoperative long-term use of
anticonvulsant agents, opiates, benzodiazepines, or
cocaine; a cardiac ejection fraction less than 40%; a his-
tory of AWR; a history of difficult intubation or antici-
pated difficult intubation; ASA physical status class 4
(those who have systemic disease that is a constant threat
to life) or class 5 (those who are not expected to survive
without the operation); aortic stenosis; end-stage lung dis-
ease; marginal exercise tolerance not resulting from mus-
culoskeletal dysfunction; pulmonary hypertension;
planned open-heart surgery; and daily alcohol consump-
tion. Patients are excluded if the surgical procedure or
positioning of the patient prevents BIS monitoring or if
the surgery requires a wake-up test. Also excluded are
patients who have dementia, who are unable to provide
informed consent, or who have a history of stroke with
residual neurological deficits.
Study Design
The design is a multi-center, prospective study, in which
6,000 patients are undergoing pre-randomization elec-
tronically in blocks of 100, with 50 patients assigned to a
BIS-guided protocol and 50 to an end tidal anesthetic gas
(ETAG)-guided protocol. Enrollment of 4,500 patients is
planned at Washington University, and enrollment of 750
patients each are planned for inclusion at University of
Chicago and at University of Manitoba. (Figure 1) Eligible
patients are undergoing randomization after providing
written informed consent. The anesthesia practitioners are
aware of the assignments of the patients, but the patients,
the postoperative interviewers, the expert reviewers, and
the statistician are not.
The manufacturer of the BIS monitor (Aspect Medical Sys-
tems) had no role in the study design, and will likewise
not be involved in data collection, data analysis, or in
manuscript preparation. No study monitors or other
means of support are being provided by Aspect Medical
Systems.
Procedures
A BIS Quatro Sensor (Aspect Medical Systems) is applied
to the left side of the forehead of each patient. The
anesthesia practitioners caring for the patients in the
ETAG group are using a monitor configuration that omits
the BIS number, so they are unaware of the BIS values. The
practitioners in both groups can view the ETAG concentra-
tions. Laminated double-sided summaries of the proto-
cols (Appendix 1) are being distributed to practitioners to
provide education and to enhance compliance.BMC Anesthesiology 2009, 9:8 http://www.biomedcentral.com/1471-2253/9/8
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Conduct of the Trial Figure 1
Conduct of the Trial.BMC Anesthesiology 2009, 9:8 http://www.biomedcentral.com/1471-2253/9/8
Page 5 of 11
(page number not for citation purposes)
In the BIS group, an audible alarm is being set to indicate
when the BIS values exceed 60 or fall below 40; no ETAG
alarms are being set in the BIS group, and there is no rec-
ommendation to maintain the ETAG concentration
within any range. In the ETAG group, an audible alarm is
being set to indicate when the ETAG concentration falls
below 0.7 age adjusted MAC or exceeds 1.3 age adjusted
MAC[19,20]. In the event that alarm settings are unavail-
able for ETAG concentration, inspired anesthetic gas
alarms are set. During cardiopulmonary bypass, the anes-
thetic-gas concentration is being measured from the efflu-
ent of the cardiopulmonary-bypass machine[21]. A sign is
being affixed to the anesthesia machines reminding the
practitioners to check the BIS value or ETAG concentra-
tion and to consider whether the patient might have intra-
operative awareness. BIS values and ETAG concentrations
are being collected at a minimum frequency of 1-minute
intervals either by electronic anesthesia recording using
Metavision®  software (iMDsoft, Needham, MA), or by
direct electronic transfer to Microsoft Excel® (Microsoft,
Redmond, WA), or by use of proprietary TrendFace Solo®
software (ixellence GmbH, Wildau, Germany). Manual
records of anesthesia and digital photographs of monitor
trends are being used as alternatives in the rare instances
that the computer data or the electronic anesthesia records
are incomplete. A composite Microsoft Access® (Microsoft,
Redmond, WA) database is being assembled, which will
incorporate all the data from the three sites and will facil-
itate subsequent analysis.
AWR is being assessed with the use of the modified Brice
questionnaire with targeted supplementary questions
(Appendix 2). The investigators are unaware of the
patients' assignments and of previous assessments of their
anesthesia awareness. Patients are contacted within 72
hours of their surgery and at 30 days after extubation. Pre-
vious studies have shown that AWR is not reliably
detected with only a single, early postoperative inter-
view[10,15]. A different investigator, who is also blinded
as to whether patients were allocated to the BIS or ETAG
protocol, contacts patients who report memories of the
period between "going to sleep" and "waking up" at either
interview, and further structured questions are asked
(Appendix 3). Patients who report such memories are all
offered referral for expert counseling.
After all patients have completed the study, three experts
who are unaware of the assignments of the patients will
independently review the questionnaire responses and
classify each patient into one of three groups: definite
AWR, possible AWR, and no AWR. In assessing whether
AWR has occurred, the experts will be instructed to focus
on memories of events that could occur only in the oper-
ating room during the anesthetic and surgical periods. The
outcome will be determined when at least two of the
experts are in agreement. If two experts hold opposing
views, a fourth expert will be asked to review the question-
naires. The experts will assign each awareness event to one
of the categories on the Michigan Awareness Classifica-
tion Instrument, which has been shown to have excellent
inter-rater agreement[22].
For each patient with either possible or definite AWR, an
investigator blinded to the intervention group will use the
accounts given by the patients and information in the
anesthetic record to identify a time window during which
anesthesia awareness was likely to have occurred. When a
specific time window cannot be identified, the entire
anesthetic period will be considered.
Secondary Outcomes
A number of secondary outcomes, including several of the
preliminary findings of the B-Unaware Trial, will be
addressed by the BAG-RECALL Trial. Some of the second-
ary outcomes will also be addressed through meta-analy-
sis including the B-Unaware, BAG-RECALL and MACS
clinical trials. The secondary outcomes are listed on the
clinical trials registration site for BAG-RECALL.
Statistical Analysis
The primary outcome measure of the study will be the
incidence of AWR in the BIS and ETAG groups. The null
hypothesis of the BAG-RECALL trial is that the BIS-guided
protocol will not decrease AWR compared with the ETAG-
guided protocol in this population. The alternative
hypothesis, for which the study is powered, is that the BIS
monitor confers a clinically significant advantage in
decreasing AWR, independent of the protocol-based care.
We based our projected estimates of AWR incidence
among higher risk patients on the results of the B-Aware
and the B-Unaware trials. With an incidence of AWR of
0.5% (5 in a 1,000) in the ETAG group and 0.1% (1 in a
1,000) in the BIS group, 3,000 patients in each group
would be sufficient to detect this difference with a one-
tailed alpha of 0.05 using Fisher's exact test (power =
87%). This represents an absolute risk reduction of 0.4%
and a number needed to treat of 250 patients at higher
risk for AWR. Any lesser absolute risk reduction would
probably be clinically unimportant and not cost effective
with the present cost of disposable BIS electrodes. We will
also use a one-sided Fisher's exact test to determine if the
BIS-guided group has a lower incidence of definite and
possible AWR. Confidence intervals for absolute risk
reduction will be calculated with the use of Newcombe's
method without continuity correction. There will be no
interim analysis. Chi-Squared, Fisher's exact, unpaired
Mann-Whitney, and unpaired t-tests will be used as
appropriate for other comparisons between the groups,
including patient characteristics and secondary outcomes.
Intention-to-treat analysis is planned. A multivariable
regression model will be used to evaluate the independent
association of specific variables with AWR and secondaryBMC Anesthesiology 2009, 9:8 http://www.biomedcentral.com/1471-2253/9/8
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outcomes. Agreement among experts assessing AWR will
be assessed using a two-way random effects intraclass cor-
relation (ICC) coefficient for absolute agreement using
the metric: no = 0, maybe = 1, yes = 2. Apart from assess-
ment of AWR, all other significance testing will be two-
sided and a P value less than 0.05 will be considered to
indicate statistical significance.
Discussion
This trial has been designed to complement two other
clinical trials: B-Unaware[15] (NCT00281489) and MACS
(NCT00689091). With the large patient numbers and
complementary rigorous designs, it is envisaged that pre-
specified meta-analyses will address some of the outstand-
ing controversies and questions relating to the potential
usefulness of processed EEG monitors in relation to pre-
venting AWR and in relation to other clinically important
outcomes.
Some important issues will remain unaddressed by BAG-
RECALL, such as: 1) Are processed EEG monitors, such as
BIS, useful in the setting of total intravenous anesthesia?
2) Is BIS the most useful processed EEG monitoring tech-
nique? 3) Do processed EEG monitors increase the likeli-
hood of AWR if they are used specifically to minimize
anesthetic dose? 4) What impact does the BIS protocol
have in settings other than the one in which this trial is
being conducted? 5) Are processed EEGs cost effective if
used routinely for all patients requiring general anesthe-
sia? 6) Does the use of nitrous oxide impact the likelihood
of AWR? As BAG-RECALL is enrolling only patients who
are considered to be at higher risk for AWR, and who are
undergoing general anesthesia with a potent inhalation
agent, the results may not be generalized beyond this
patient population. If the BIS protocol is associated with a
reduction in AWR, it does not rule out the possibility that
it would be associated with no reduction or even an
increased incidence of AWR in other patient populations.
This emphasizes the importance of our companion trial,
MACS (NCT00689091), which is enrolling all surgical
patients, regardless of perceived risk.
An important assumption underlying the design of the
BAG-RECALL trial is that risk factors for AWR are known
and patients with increased risk can be identified and
enrolled. However, if there are unidentified risk factors for
AWR, such as genetic resistance to the hypnotic or amnes-
tic actions of anesthetic agents, and if these are relatively
common compared with the risk factors that have been
used to identify eligible patients for BAG-RECALL, this
could be an important hidden confounder. If the uniden-
tified risk factors are distributed unequally between the
BIS and ETAG groups, this could confound the results of
the trial independent of the BIS and ETAG protocols. With
rare risk factors and an even rarer outcome (i.e., AWR), it
is not certain that randomization alone will result in equal
assignment of patients with hidden risk factors to each
group.
One of the most important reasons to prevent AWR is to
prevent long-term psychological symptoms and the devel-
opment of PTSD. While assessing psychological conse-
quences is an important secondary outcome of BAG-
RECALL, it may not be valid to apply the results of BAG-
RECALL to patients who suffer AWR in general. The rea-
son for this is that all patients who experience AWR are
referred to an expert counselor whose intervention may
mitigate the psychological sequelae of AWR.
A criticism leveled against the B-Unaware trial was that the
control group also used a protocol, which was not reflec-
tive of current standard practice. For the B-Unaware, the
BAG RECALL, and MACS clinical trials, we have designed
protocols that are simple and easy to implement at no cost
over current practice. We have stressed that the protocols
are not intended to be restrictive, but are merely intended
to increase vigilance and possibly to provide earlier warn-
ing when awareness is more likely to occur. If processed
EEG monitors, such as the BIS, are to enjoy widespread
adoption, they must confer advantage over the best, sim-
ple alternative practice, not just usual care.
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Appendix 1: Protocols
BIS Protocol
1) The protocol is intended as a rough guide, not to be
prescriptive.
2) BIS alarms are set to alert, not to restrict.
3) The BIS is intended to guide practitioners in two chief
ways:
a. Provide sufficient anesthesia for "hypnotic" com-
ponent GA.BMC Anesthesiology 2009, 9:8 http://www.biomedcentral.com/1471-2253/9/8
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b. Decrease anesthesia safely to minimize the mean
anesthetic dose.
4) Ideally anesthesia should be titrated such that the BIS
is maintained between 40 and 60, or alternatively,
between 45 and 60 during surgery. During skin closure,
anesthesia may be lightened, ideally keeping the BIS < 75.
5) The BIS should be interpreted in context, taking into
account patient characteristics, surgical stimulation,
hemodynamic parameters, analgesic administration, use
of regional anesthesia, extent of muscle relaxation, anes-
thetic gas concentration, and other data provided by the
BIS monitor.
6) Reliance on the BIS alone is not recommended. Arti-
facts and poor signal quality may lead to inappropriate
BIS values. Artifacts may be caused by poor skin contact
(high impedance), muscle activity or rigidity, head and
body motion, sustained eye movements, improper sensor
placement and electrical interference. BIS should be inter-
preted cautiously in patients with neurological disorders
and those taking psychoactive medications.
7) With deepening anesthesia, apart from a BIS decrease,
there are changes in other EEG-derived parameters that
are readily available on the monitor:
a. EEG may be set on a 50 μV scale at a sweep speed of
50 mm/sec. A typical adult EEG signal is 10 μV to 100
μV in amplitude when measured from the scalp. Sim-
plistically, the EEG shows slowing (decreasing fre-
quency in Hz) and increasing amplitude with
deepening anesthesia.
i. Gamma (30-70 Hz)
ii. Beta (12-30 Hz)
iii. Alpha (8-12 Hz), sleep spindles, K complexes
iv. Theta (4-8 Hz)
v. Delta (< 4 Hz)
vi. Burst suppressionvii. Iso-electricityb. SEF -
The frequency (from 0.5 - 30.00 Hz) at which 95%
of the total EEG power lies below it and 5% lies
above it. Lower SEFs are in keeping with deeper
anesthesia.
c. SR - There may be periods of flat EEG trace (burst
suppression), which may progress to a flat line or iso-
electricity. Suppression ratio (SR) is the % of time (0-
100%) over the last 63-sec period that the EEG signal
is in the "suppressed" state.
8) When there is excessive muscle activity, there is a pos-
sibility that the BIS may be falsely elevated. The EMG
shows the power (from 30-80 decibels) in the frequency
range 70 - 110 Hz.
9) SQI is a calculated measure of the signal quality (from
0-100) for the EEG channel source(s).
10) BIS Smoothing Rate should be set at 15 sec. to pro-
vide increased responsiveness to state changes, such as
induction or awakening.
ETAG Protocol
1) The protocol is intended as a rough guide, not to be
prescriptive.
2) ETAG alarms are set to alert, not to restrict.
3) On some machines, anesthesia gas alarms are available
only for inspired anesthetic gas. With low flow anesthe-
sia and when the anesthesia dose (vaporizer) is adjusted,
there may be discrepancies between inspired anesthesia
gas and end-tidal anesthesia gas (ETAG).
4) Ideally anesthesia should be titrated such that the
ETAG is maintained between 0.7 and 1.3 age-adjusted
MAC during surgery. During skin closure, the anesthetic
gas may be turned down at the discretion of the anesthe-
sia practitioner.
5) MAC-awake is about 1/3 MAC for desflurane, sevoflu-
rane and isoflurane.
6) There is evidence that at twice MAC-awake (about 0.7
MAC), even distressing (auditory) stimuli are not inter-
nalized.
7) The ETAG should be interpreted in context, taking
into account patient characteristics, surgical stimulation,
hemodynamic parameters, analgesic administration, and
use of regional anesthesia.
8) Age has an important bearing on MAC.
9) The age-adjusted MAC values [and 0.7-1.3 MAC
ranges] are given below:
(At sea level, 1 KPa anesthetic gas is approximately equal
to 1%)
a. Desflurane:
i. Age 18-39: 7 KPa [4.9 to 9.1 KPa]
ii. Age 40-59: 6 KPa [4.2 to 7.8 KPa]BMC Anesthesiology 2009, 9:8 http://www.biomedcentral.com/1471-2253/9/8
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iii. Age 60-79: 5.2 KPa [3.6 to 6.8 KPa]
iv. Age ≥80: 4.55 KPa [3.2 to 5.9 KPa]
b. Sevoflurane:
i. Age 18-39: 2.4 KPa [1.7 to 3.1 KPa]
ii. Age 40-59: 1.7 KPa [1.2 to 2.2 KPa]
iii. Age 60-79: 1.55 KPa [1.1 to 2.0 KPa]
iv. Age ≥80: 1.2 KPa [0.8 to 1.6 KPa]
c. Isoflurane:
i. Age 18-39: 1.3 KPa [0.9 to 1.7 KPa]
ii. Age 40-59: 1.1 KPa [0.8 to 1.4 KPa]
iii. Age 60-79: 1.0 KPa [0.7 to 1.3 KPa]
iv. Age ≥80: 0.8 KPa [0.6 to 1.0 KPa]
10) You should be blinded to the BIS number, the EEG
trace, and all the EEG-derived parameters, apart from the
SQI (signal quality index).
Appendix 2: Postoperative Questionnaire
Title of Study: BAG-RECALL: BIS or Anesthesia Gas to
Reduce Explicit RecallExtubation date: ______________
______________ Interviewer's Initials________
Today's date: ____________________________________
1. What is the last thing you remember before going to
sleep?
-Being in the pre-op area
-Seeing the operating room
-Being with family
-Hearing voices
-Feeling mask on face
-Smell of gas
-Burning or stinging in the IV line
-Other [Free Text]: _________________________________
______________
2. What is the first thing you remember after waking
up?
-Hearing voices
-Feeling breathing tube
-Feeling mask on face
-Feeling pain
-Seeing the operating room
-Being in the recovery room
-Being with family
-Being in ICU
-Nothing
-Other [Free Text]: ______________________________
_________________
3. Do you remember anything between going to sleep
and waking up?
-No
-Yes:-Hearing voices
-Hearing events of the surgery
-Unable to move or breathe
-Anxiety/stress
-Feeling pain
-Sensation of breathing tube
-Feeling surgery without pain
-Other [Free Text]: ______________________________
________________
4.) Did you dream during your procedure?
-No
-Yes
-What about [Free Text]: _______________________
________ BMC Anesthesiology 2009, 9:8 http://www.biomedcentral.com/1471-2253/9/8
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5.) Were your dreams disturbing to you?
-No
-Yes
6.) Did you experience any nausea or vomiting follow-
ing your operation?
-No
-Yes
If yes, how many times? _________
7.) What was the worst thing about your operation?
-Anxiety
-Pain
-Recovery process
-Functional limitations
-Awareness
-Other [Free Text]: ______________________________
_________________
8.) Are you left or right handed?
-left
-right
9.) Are you a natural red head?
- Yes
- No
10.) Regarding your regular sleep, how often do you
remember your dreams?
- Never
-Every few weeks
-At least once a week
-Daily
11.) Do you make any effort to remember your dreams?
-No
-Yes
If yes, how?____________________________________
____________________
Appendix 3: Structured follow-up questionnaire 
for patients who report memories of the period 
between "going to sleep" and "waking up" at 
either routine postoperative interview
1) When we contacted you about your surgery, you men-
tioned that you remembered something between going to
sleep at the beginning of your surgery and waking at the
end of your surgery. Do you still have memories of events
that occurred during your surgery?
2) What do you remember?
a. Did you hear anything? (What?)
i) Voices (gender)
ii) Specific words
iii) Music
iv) Other
b. Did you any emotions? (What?)
i) Happiness
ii) Fear
iii) Calm
iv) Helplessness
v) Other
c. Did you experience any sensations?
i) Warmth
ii) Pressure
iii) Cold
iv) Pain
v) Other
d. Did you try to move? If yes, could you?BMC Anesthesiology 2009, 9:8 http://www.biomedcentral.com/1471-2253/9/8
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e. What was your breathing like?
i) Normal
ii) Fast
iii) Labored
iv) Unable to breathe
v) Other
f. Did you see anything? What did you see?
i) Light
ii) Colors
iii) Shapes
iv) Specific image
v) Other
g. Did you try to open your eyes? If yes, could you?
h. Were you afraid?
i. Did the experience distress you?
3) Do these memories trouble you?
4) If yes, how do they trouble you?
a. Have you experienced stress?
b. Have you felt any negative emotions because of
them?
i) Fear
ii) Helplessness
iii) Anger
iv) Frustration
v) Other
c. Do you avoid any situations as a result of your expe-
riences?
d. Do you experience waking flashbacks?
e. Do you have bad dreams?
f. Has your social life been affected?
5) Did you go to the intensive care unit after your surgery?
If yes, did you still have the breathing tube in?
6) Did your awareness experience occur before the start of
the surgery, during the surgery or when you were waking
up from the surgery?
7) Do you think your awareness experience took place in
the operating room or in the intensive care unit or both?
Why do you think this?
8) Have you spoken to a health counselor about these
experiences?
9) Do you suffer from insomnia?
10) Are you easily awakened from regular sleep?
11) Do you remember your dreams during regular sleep?
12) Would you like to speak to a professional about your
experiences? We can give you a number of a professional
who can see you.
13) Is it all right with you if we contact you again to talk
to you about your experiences?
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